Table 4. Safety Outcomes of 42 Participants a.
| CBD/Δ9-THC (10:1) Group (n = 24) | Placebo Group (n = 22) | P-Value | |
|---|---|---|---|
| Rashes | 0 (0) | 0 (0) | 1 |
| Purities | 0 (0) | 0 (0) | 1 |
| Itching | 0 (0) | 0 (0) | 1 |
| Dry mouth | 0 (0) | 0 (0) | 1 |
| Headache | 1 (4.17) | 0 (0) | 0.99 |
| Nausea | 0 (0) | 0 (0) | 1 |
| Vomiting | 0 (0) | 0 (0) | 1 |
| Loss of appetite | 1 (4.17) | 1 (4.54) | 0.99 |
| Dizziness | 1 (4.17) | 0 (0) | 0.99 |
| Vertigo | 1 (4.17) | 0 (0) | 0.99 |
| Hypotension/hypertension | 0 (0) | 0 (0) | 1 |
| Lethargy | 0 (0) | 0 (0) | 1 |
| Diarrhea/constipation | 0 (0) | 0 (0) | 1 |
| Severe hypoglycemia | 0 (0) | 0 (0) | 1 |
| Blurred vision | 0 (0) | 0 (0) | 1 |
| Weight gain/loss | 0 (0) | 0 (0) | 1 |
| GI distress | 0 (0) | 0 (0) | 1 |
| Other | 2 (8.34) | 1 (4.54) | 0.99 |
a Values are expressed as No. (%).